drugset
drugset / Trial / NCT04650581

Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor

NCT04650581 ↗

Phase 3 Active not recruiting 250 enrolled Canadian Cancer Trials Group Hoffmann-La Roche · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to find out whether a new drug, Ipatasertib, can slow the growth of advanced breast cancer when added to standard therapy (Fulvestrant).

Timeline

Start
2021-01-27
Primary completion
2025-05-23
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Ipatasertib Small molecule 400 mg Oral
Background Fulvestrant Small molecule 500 mg Intramuscular

Indications

breast cancer